Tyrosine Kinase Inhibitors in Glioblastoma: Refining Precision Medicine

Download All
In this online program, experts discuss recent advances in the use of tyrosine kinase inhibitors to optimize outcomes in patients with glioblastoma. Watch the on-demand Webcast and download the slides from a dynamic CCO symposium to learn more about how to optimize this approach in your clinical practice.
Tom Mikkelsen, MD, FRCPC
Program Director
Manmeet S. Ahluwalia, MD, FACP
Rimas V. Lukas, MD
Tom Mikkelsen, MD, FRCPC

On-Demand Webcast

In this CME-certified, on-demand Webcast of a CCO symposium at SNO 2019, a panel of expert faculty reviews and discusses the latest data on the use of tyrosine kinase inhibitors for the treatment of glioblastoma.

Tom Mikkelsen, MD, FRCPC
Program Director
Manmeet S. Ahluwalia, MD, FACP Rimas V. Lukas, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: January 17, 2020 Expired: No longer available for credit

Downloadable Slidesets

In this downloadable slideset, Rimas V. Lukas, MD, spotlights NTRK fusions and TRK-targeted therapies for patients with GBM.

Rimas V. Lukas, MD Released: November 22, 2019

In this downloadable slideset, Manmeet S. Ahluwalia, MD, FACP, highlights regorafenib in the REGOMA trial and other multiple receptor kinase inhibitors for patients with GBM.

Manmeet S. Ahluwalia, MD, FACP Released: November 22, 2019

In this downloadable slideset, Tom Mikkelsen, MD, FRCPC, examines optimal clinical trial approaches for GBM therapies.

Tom Mikkelsen, MD, FRCPC Released: November 22, 2019
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings